focus -WSS

focus

author：hotspot 2025-09-30 13:13:59 - browse：976

Novo Nordisk Denmark — LISELOTTE SABROE/AFP/Getty Images

An oral version of semaglutide, the drug marketed as Ozempic and Wegovy, led to dramatic weight loss in a trial enrolling people with obesity, manufacturer Novo Nordisk said Monday, data that could bolster what is already a blockbuster medicine.

In the study, which enrolled nearly 700 adults classified as having overweight or obesity, patients treated with a daily semaglutide tablet lost 15.1% of their body weight over the course of 17 months, while those on placebo lost 2.4%, Novo Nordisk said. The result is comparable to weekly injections of Wegovy, which in an earlier study led to 14.9% weight loss over the same period of time. In both studies, the most common side effects were gastrointestinal distress, with the majority of cases graded mild or moderate, the company said.

Novo Nordisk said it plans to submit oral semaglutide for U.S. and E.U. approvals later this year. A lower-dose version of the drug is already approved as a treatment for type 2 diabetes under the brand name Rybelsus.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical records are filled with copy
Next article： Oral obesity drug from Viking Therapeutics hits key early target

focus

WSS

EPA limits use of carcinogenic gas for sterilizing medical devices

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

U.K. decision on ALS drug has neurologists, advocates up in arms

EPA limits use of carcinogenic gas for sterilizing medical devices

Overprescribed: High cost isn't America's only drug problem

Multiple sclerosis has subtypes with different best treatments: study

focus

focus

hotspot

United colonoscopy coverage change 'may cost lives,' doctors say

UnitedHealth, in a surprise, takes aim at Steward’s physician group

Guidelines to prevent youth baseball injuries need more muscle

Bird flu in dairy cattle: New measures to control spread to humans

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Amid AI frenzy, a top HHS official's quest to create safeguards

BioMarin wins approval for gene therapy to treat hemophilia A

Medicare coverage of Wegovy, once blocked, now looks possible

Guidelines to prevent youth baseball injuries need more muscle

Bird flu reported in person exposed to presumably infected cattle

focus

Young boy dies in trial for Pfizer Duchenne gene therapy

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

Oral obesity drug from Viking Therapeutics hits key early target

How to save health care price transparency rules

Readout Newsletter: CAR

Change Healthcare outage fallout shows need for new oversight

entertainment

focus

hotspot

hotspot